3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
8
Salivary Gland Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Pathologic Complete Response
1
Hemangiosarcoma
1
Heart Failure
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Breast Cancer
1
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Brain Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
pyrotinib
1
pertuzumab
1
disitamab vedotin
1
Trastuzumab
1
RC48 antibody
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
HER2-positive Metastatic Breast Cancer
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT06595563
2026-05-07
ZEPHIR-02
Jules Bordet Institute
Phase 2
Recruiting
87 enrolled